Abstract
One million people throughout the world are bitten yearly by poisonous snakes. Of this, one-tenth died and three-tenth suffer some forms of disabilities. In view of this, anti-snake venoms are currently being developed against viper and colubrid snake venoms using mice. Therefore, a new algorithm for calculation of median lethal dose (LD50) and effective dose fifty (ED50) was developed for Micrarus fulvius venom and antivenom respectively. This paper compared the formula of effective dose fifty (ED50) developed by Spearman and Karber with ideal median lethal dose (IMLD50) formula developed by Saganuwan with a view to bringing out their difference and similarity in calculation of ED50 that could be used to develop a new median lethal dose formula for calculation of Micrarus fulvius venom in mice. The findings revealed that ED50 value (477 mg/kg) from Spearman and Karber’s formula ( is comparatively similar with ideal median lethal dose value (428.75 mg/kg) from Saganuwan’s formula (MLD50 + MSD50/2). The new LD50 formula () yielded value (0.29 mg/kg) of comparative significance with reported value (0.32 mg/kg). When ED50 is equal to 2LD50, the denominator of becomes 2. In conclusion, the new formula would yield low doses of snake anti-venoms with reduced possibility of hypersensitivity reaction.
Keywords: Effective dose, Median lethal dose, Snake venom, Snake anti venom, Mice, Micrarus fulvius
1. Introduction
Snakes are represented on earth today by some 3150 species [1]. Of these 2700 species known as Caenophidia or “advanced snakes” with fangs, and venom glands [2]. Venomous snakes are responsible for an estimated 75,000 human deaths annually [3]. In the United Sates approximately 45,000 snake bites occur each year, of which about 8000 are by 20 species of venomous snakes. Deaths do not exceed 10–12 per year [4]. Of hospitalized snakebite victims, 0.5% of bites were inflicted by coral snakes, 7.3% by cottonmouths, 28.6% by copper heads, 29.8% by unidentified snakes and 33% by rattlesnake [5] with diamondbacks causing the most fatalities. More than 95% of bites occur between April and October and 77% occur during day time [6]. Snake venom metalloproteinases are responsible for major local symptoms in snakebite causing haemorrhage, oedema, hypotension, hypovolemia, inflammation and necrosis [7]. Because of considerable ophidic snake bites, advances have been achieved in the production of new antivenoms using new processes [8], Coral snake envenomation could be handled using medication [9]. Specific treatments with antivenoms continue to be the chosen method as it deactivates the venom [10]. Aguilar et al. [11] prepared snake antivenom against Micranis fulvius in chicken (Gallis domesticus) with median effective dose (ED50 = 477 mg/kg). Because of hypersensitivity reactions that do result from snake antivenom treatment, a new algorithm has been developed for calculation of median lethal dose (LD50) and effective dose fifty (ED50) for snake venom and antiveonom respectively.
2. Materials and methods
Reed and Muench [12] introduced arithmetical method for determination of median lethal dose (LD50) in 1938 which was modified by Saganuwan [13]. The possible modifications involved calculating percent of test animals both that died and survived at all the test dose levels. The average of a dose that caused 50% death and another dose that caused 50% survival gave a relatively ideal LD50. However, Aguilar et al. [11] estimated effective dose fifty (ED50) of coral snake antivenom according to the method of Spearman and Karber [14] using mice of 18–20 g. Various antivenom concentrations of 17.2, 8.6, 4.3, 21.5 and 5.3 mg per mouse weighing 20 g were used for calculation of Ideal Median Lethal Dose (IMLD50) proven to be comparatively similar to the Effective Dose Fifty (ED50) calculated by Aguilar et al. [11] using Spearman and Karber’s formula. ED50 was also used to develop a new formula for calculation of median lethal dose (LD50) of snake venom in mice.
2.1. Definition of terms
ED50 = the 50% effective dose; log X100 = log dose giving 100% survival and having 100% survival for all higher doses; log FD = the log dilution factor; N = number of mice used at each dose level; Σ = the sum of mice surviving at every dose level, the ED50 is the effective dose of (lgy) that will protect 50% of the mice population when injected with 3LD50s. Median lethal dose (MLD50) is the dose that kills 50% of test mice whereas median survival dose (MSD50) is the dose survival by 50% of test mice.
2.2. Ideal median lethal dose (IMLD50) of snake venom is equal to effective dose fifty (ED50) of snake antivenom in mice
The calculation done by Aguilar et al. [11] for determination of ED50 is confirmed using Ideal Median Lethal Dose (MLD50) formula of Saganuwan [13] proving that Spearman and Karber’s formula gives ED50 that approximates Ideal Median Lethal Dose (LD50).
2.3. Hypothesis
2.4. Median Lethal Dose of Snake Venom Deduced from Effective Dose Fifty (ED50) and Ideal Median Lethal Dose (IMLD50)
Since ED50 is the effective dose of 1gy that will protect 50% of the mouse population when injected with 3LD50, the LD50 of venom in the present context should be determined as follows:
ED50 = 3LD50
(this cannot give correct LD50 value)
-
i.
But there is need to know the weight of individual mouse in gramme (Wm) in relation to that of human in kilogramme (1000 g) since antivenom is developed for human use.
-
ii.
Also safety factor of 1/10 is considered for mouse as compared to snake
3. Results
Proof: Ideal Median Lethal Dose (IMLD50) of Snake Venom is Equal to Effective Dose (ED50) of Snake Antivenom in Mice
Dose log dose | |
21.5 1.3324 | log 2.5 = 0.3979 |
8.6 0.9344 | 0.333 × 0.3979 |
=0.398 | 0.1325007 |
∴ 0.666 × 0.3989 = 0.265068 | |
Antilog of 0.9344 + 0.265068 | Antilog of 0.9344 × 0.1325007 |
=1.199468 | =0.12380 |
MLD50 = 15.82 mg/mouse | =1.32 |
MSD50 = 1.33 mg/mouse | |
=8.75 mg/mouse |
Proof: New Median Lethal Dose of Snake Venom Deduced from Effective Dose Fifty (ED50) and Ideal Median Lethal Dose (IMLD50)
The ED50 is the effective dose of Igy that will protect 50% of the mouse population when injected with 3LD50 (Table 1).
Average weighed mouse is 20 g |
∴ 8.575 mg → 20 g |
x → 1000 g |
But the ED50 reported by Aguilar et al. [1] is 477 mg/kg |
But IMLD50 = 451.3 mg/kg |
∴ |
LD50 = 0.29 mg/kg |
IMLD50 ≃ ED50 |
∴ IMLD50 can be used to calculate ED50 |
Table 1.
Total protein of antivenom (mg/20 g mouse) | Log dose | Cumulative |
|||||||
---|---|---|---|---|---|---|---|---|---|
Dead | Survived | Dead | Survived | Total | Mortality rate | % Mortality | % Survival | ||
17.2 | 1.2355 | 0 | 8 | 0 | 8 | 8 | 0.0 | 100 | |
8.6 | 0.9344 | 4 | 4 | 4 | 12 | 16 | 25.0 | 75 | |
4.3 | 0.6334 | 8 | 0 | 12 | 12 | 24 | 50.0 | 50.0 | |
21.5 | 1.3324 | 8 | 0 | 20 | 12 | 32 | 62.5 | 37.5 | |
5.3 | 0.7242 | 8 | 0 | 28 | 12 | 40 | 70.0 | 30 |
4. Discussion
The IMLD50 (428.75 mg/kg) obtained in our present investigation is close to the ED50 value (477 mg/kg) reported by Aguilar et al. [11] indicating that IMLD50 can be used to calculate ED50 of snake antivenom. The two values are within the acceptable ED50 ranges of other antivenoms tested on different snake venoms [15]. Normally antivenoms are achieved by immunizing horses with increasing doses of venom to obtain a high-quality antibody titer [16]. But since the value of our IMLD50 is little lower than that of Aguilar et al., it may connote that at lower level of ED50, low side effects including anaphylaxis may exist. The elevated concentrations of proteins, which are not antibodies, existing in many antivenoms produce most of these side effects [17]. Immunoglobulin (Igy) produce antibody against M. isozomus [11] and Scolapadra gigaitea toxin [18]. WHO [14] patented Sodium Silicate Complex (SSC) which comprises Trimeric Sodium Silicate (Na2SiO3) and Sodium Silicate Pentahydrate (Na2SiO3)·5H2O using a relatively ideal median lethal dose formula developed by Saganuwan [13] confirming the reliability, predictive validity and precision of the formula. SSC has antivenomous activity against Crotalus atrox, Agkistrodon contortrix contortrix and Agkistrodon piscivorus leucostoma venoms [14] of our estimated LD50 (0.29 mg/kg) using the new developed formula agrees with the report of Aguilar et al. [11] indicating that the LD50 of Micrarus fulvius in mice is 0.32 ± 0.12 mg/kg body weight in mice.
Snake venoms are known to be the most complex of all natural venoms. They contain more than one hundred toxic and non-toxic biological molecules [19]. The cell toxicity assay has been adapted as an alternative to assess toxicity in animals [20]. In the 1960s and 1970s, mice became the universally accepted test animals and comparative toxicity was expressed as LD50. Since ideal median lethal dose is approximately equal to effective safety dose fifty (ED50) of antivenom and now LD50 formula is deduced from ED50, the two formulas can be of great value in toxinology of snake venom and anti-venom.
5. Conclusion
In line with the principles of replacement, reduction and refinement, ideal median lethal dose and new developed LD50 formula can be of great use for assessment of snake antivenom and snake venom respectively. In conclusion, the new formula would yield low doses of snake anti-venoms with reduced possibility of hypersensitivity reaction.
Footnotes
Peer review under responsibility of Faculty of Veterinary Medicine, Cairo University.
References
- 1.Vidal N., Delmas A.S., David P., Cruaud C. The phylogeny and classification of caenophidian snakes inferrerd from seven nuclear protein-coding genes. C R Biol. 2007;330:182–187. doi: 10.1016/j.crvi.2006.10.001. [DOI] [PubMed] [Google Scholar]
- 2.Vonk F.J., Jackson K., Doley R., Madaras F., Mirtschin P.J., Vidal N. Snake venom: from field work to the clinic. BioEssays. 2011;33:269–279. doi: 10.1002/bies.201000117. [DOI] [PubMed] [Google Scholar]
- 3.Synder C.C. Animal bite wounds. Hand Clin. 1989;5:571–590. [PubMed] [Google Scholar]
- 4.Nelson B.K. Snake envenomation. Incidence, clinical presentation and management. Med Toxicol Adverse Drug Exp. 1989;4:17–31. doi: 10.1007/BF03259900. [DOI] [PubMed] [Google Scholar]
- 5.Parrish H.M. Incidence of treated snakebites in the United States. Public Health Ref. 1966;81:269–276. [PMC free article] [PubMed] [Google Scholar]
- 6.Blackman J.R., Dillon S. Venomous snakebite: Past, present and future treatment options. JABFP. 1992;5(4):399–405. [PubMed] [Google Scholar]
- 7.Hite L.A., Jia L.G., Bjarmason J.B., Fox J.W. CDNA sequluces for four snake venom metallo proteinases: structure, classification and their relationship to mammalian reproductive proteins. Arch Biochem Biophys. 1994;308:182–191. doi: 10.1006/abbi.1994.1026. [DOI] [PubMed] [Google Scholar]
- 8.Almeida C.M., Kanashiro M.M., Ranged Filho F.B., Mata M.F., Kipnis T.L., da Silva W.D. Development of snake antivenom antibodies in chickens and their purification from yolk. Vet Rec. 1998;143:579–584. doi: 10.1136/vr.143.21.579. [DOI] [PubMed] [Google Scholar]
- 9.Araujo A.S., Labato Z.L., Chavez – Olortegui C., Velarde D.T. Brazilian igy – Bothrops – antivenom: studies on the development of a process in chicken egg yolk. Toxicon. 2010;55:739–744. doi: 10.1016/j.toxicon.2009.11.004. [DOI] [PubMed] [Google Scholar]
- 10.Christensen P.A. Production and standardization of antivenin. In: Lee C.Y., editor. Handbook of experimental pharmacology. Springer-Verlag; New York: 1979. pp. 1–325. [Google Scholar]
- 11.Aguilar I., Sanches E.E., Giron M.E., Estrella A., Guerrero B., Rodriquez – Acosta F.L. Coral snake antivenom produced in chickens (Gallus domesticus) Rev Inst Med Trop Sao Paulo. 2014;56(1):61–66. doi: 10.1590/S0036-46652014000100009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Reed L.J., Muench H. A simple method of estimating fifty percent end points. Am J Hyg. 1938;27:493–497. [Google Scholar]
- 13.Saganuwan S.A. A modified arithmetical method of Reed and Muench for determination of a relatively ideal median lethal dose (LD50) Afr J Pharm Pharmacol. 2011;5(12):1543–1546. [Google Scholar]
- 14.World Health Organization Progress in the characterization of venoms and standardization of antiveonoms. WHO Offset Publ. 2014;58:1–44. [PubMed] [Google Scholar]
- 15.Devi C.M., Bai M.V., Lal A.V., Umashankar P.R., Krishnan L.K. An improved method for isolation of anti-viper venom antibodies from chicken egg yolk. J Biochem Biophys Methods. 2002;51:129–138. doi: 10.1016/s0165-022x(02)00002-7. [DOI] [PubMed] [Google Scholar]
- 16.Estrada R., Chaves F., Robles A., Rojas E., Segura E., Gutierrez J.M. Valores hematologicus y de enzimas sericas en caballes inocukdas com venenos de sepientes paraLa productum de antivenenos enCosta Rica. Rev Biol Trop. 1992;40:95–99. [PubMed] [Google Scholar]
- 17.Schellekens H. How to prodict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev. 2008;14:191–202. doi: 10.1016/S1387-2656(08)00007-0. [DOI] [PubMed] [Google Scholar]
- 18.Parilla P., Navarrete L.F., Giran M.E., Aguilar I., Rodrigues - Acosta A. Use of Chicken egg-derived immunoglobulin against Scolopendra venomas an alternative to treat scolopendrism. Rev Cient FCV – LUZ. 2008;18:385–392. [Google Scholar]
- 19.Bieber A.L. Metal and nonprotein constituents in snake venoms. In: Lee C.Y., editor. Snake venoms. Handbook of Experimental Pharmacology. Springer Verlag; Berlin, Germany: 1979. pp. 295–306. [Google Scholar]
- 20.Oliveira J.C.R., Montes de Oca H., Duarte M.M., Diniz C.R., Fortes-Dias C.L. Toxicity of South American Snake Venoms measured by an in vitro cell culture assay. Toxicon. 2002;40(3):321–325. doi: 10.1016/s0041-0101(01)00229-x. [DOI] [PubMed] [Google Scholar]